论文部分内容阅读
目的分析低分子肝素对预防孕产期肺栓塞的应用价值。方法选取2013年10月至2014年10月江门市新会区第二人民医院产科收治的300例具有血栓形成危险因素患者的临床资料,随机分为观察组及对照组,每组150例。对照组采取常规治疗,观察组接受低分子肝素治疗,对比两组患者的临床防治效果。结果观察组肺栓塞发生率为0.67%,明显低于对照组的8.00%,差异有统计学意义(P<0.05)。观察组胎盘早剥、产后出血分别为2.00%、3.33%,与对照组的2.67%、4.00%对比,差异未见统计学意义(P>0.05)。治疗前后,观察组PT、PLT水平对比,差异未见统计学意义(P>0.05)。治疗后,观察组D-dimer、Fbg水平分别为(1.32±0.51)mg/L、(4.42±0.45)g/L,明显低于治疗前的(3.48±0.86)mg/L、(7.38±0.20)g/L,差异有统计学意义(P<0.05)。两组患者的红细胞、血小板、纤维蛋白原、凝血酶原时间、凝血酶时间等指标对比,差异未见统计学意义(P>0.05)。结论低分子肝素可有效防治孕产期肺栓塞,具有明显的安全性、有效性,充分改善高凝状态,促进患者病情康复,值得临床推广应用。
Objective To analyze the value of low molecular weight heparin in preventing maternal pulmonary embolism. Methods From October 2013 to October 2014, 300 patients with risk factors of thrombosis admitted to the Second People’s Hospital of Xinhui District, Jiangmen City were randomly divided into observation group and control group, with 150 cases in each group. The control group to take conventional treatment, the observation group received low molecular weight heparin treatment, the two groups of patients compared to the clinical control effect. Results The incidence of pulmonary embolism in the observation group was 0.67%, which was significantly lower than that in the control group (8.00%), the difference was statistically significant (P <0.05). In the observation group, the rates of placental abruption and postpartum hemorrhage were 2.00% and 3.33%, respectively. Compared with the control group, 2.67% and 4.00%, the difference was not statistically significant (P> 0.05). Before and after treatment, the observation group PT, PLT levels, the difference was not statistically significant (P> 0.05). After treatment, the levels of D-dimer and Fbg in observation group were (1.32 ± 0.51) mg / L and (4.42 ± 0.45) g / L respectively, which were significantly lower than those before treatment (3.48 ± 0.86) mg / ) g / L, the difference was statistically significant (P <0.05). The difference of erythrocyte, platelet, fibrinogen, prothrombin time, thrombin time between the two groups showed no significant difference (P> 0.05). Conclusion Low molecular weight heparin can effectively prevent and treat maternal pulmonary embolism. It has obvious safety and effectiveness, fully improves the hypercoagulable state, and promotes the recovery of patients. It is worthy of clinical application.